ID   NEK2_HUMAN              Reviewed;         445 AA.
AC   P51955; Q53FD6; Q5I1Z9; Q5VXZ1; Q6NZX8; Q7Z634; Q86XH2; Q96QN9;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-OCT-2022, entry version 225.
DE   RecName: Full=Serine/threonine-protein kinase Nek2;
DE            EC=2.7.11.1;
DE   AltName: Full=HSPK 21;
DE   AltName: Full=Never in mitosis A-related kinase 2;
DE            Short=NimA-related protein kinase 2;
DE   AltName: Full=NimA-like protein kinase 1;
GN   Name=NEK2; Synonyms=NEK2A, NLK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Nasopharynx, Placenta, and T-cell;
RX   PubMed=7522034;
RA   Schultz S.J., Fry A.M., Suetterlin C., Ried T., Nigg E.A.;
RT   "Cell cycle-dependent expression of Nek2, a novel human protein kinase
RT   related to the NIMA mitotic regulator of Aspergillus nidulans.";
RL   Cell Growth Differ. 5:625-635(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, DIMERIZATION, AND
RP   INDUCTION.
RX   PubMed=11742531; DOI=10.1042/0264-6021:3610077;
RA   Hames R.S., Fry A.M.;
RT   "Alternative splice variants of the human centrosome kinase Nek2 exhibit
RT   distinct patterns of expression in mitosis.";
RL   Biochem. J. 361:77-85(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Lu K.P., Hunter T.;
RT   "Molecular cloning and expression of NLK1, a human NIMA-like kinase.";
RL   Submitted (JUL-1994) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-354.
RC   TISSUE=Testis;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Mammary gland, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 83-203.
RX   PubMed=8274451;
RA   Schultz S.J., Nigg E.A.;
RT   "Identification of 21 novel human protein kinases, including 3 members of a
RT   family related to the cell cycle regulator nimA of Aspergillus nidulans.";
RL   Cell Growth Differ. 4:821-830(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 216-445 (ISOFORM 4), INTERACTION WITH PPP1CC,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=15659832; DOI=10.1196/annals.1329.059;
RA   Fardilha M., Wu W., Sa R., Fidalgo S., Sousa C., Mota C.,
RA   da Cruz e Silva O.A., da Cruz e Silva E.F.;
RT   "Alternatively spliced protein variants as potential therapeutic targets
RT   for male infertility and contraception.";
RL   Ann. N. Y. Acad. Sci. 1030:468-478(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 305-445, FUNCTION, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH MAD1L1.
RX   PubMed=14978040; DOI=10.1074/jbc.m314205200;
RA   Lou Y., Yao J., Zereshki A., Dou Z., Ahmed K., Wang H., Hu J., Wang Y.,
RA   Yao X.;
RT   "NEK2A interacts with MAD1 and possibly functions as a novel integrator of
RT   the spindle checkpoint signaling.";
RL   J. Biol. Chem. 279:20049-20057(2004).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12857871; DOI=10.1091/mbc.e03-02-0108;
RA   Faragher A.J., Fry A.M.;
RT   "Nek2A kinase stimulates centrosome disjunction and is required for
RT   formation of bipolar mitotic spindles.";
RL   Mol. Biol. Cell 14:2876-2889(2003).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAPK1.
RX   PubMed=15358203; DOI=10.1016/j.bbrc.2004.06.171;
RA   Lou Y., Xie W., Zhang D.F., Yao J.H., Luo Z.F., Wang Y.Z., Shi Y.Y.,
RA   Yao X.B.;
RT   "Nek2A specifies the centrosomal localization of Erk2.";
RL   Biochem. Biophys. Res. Commun. 321:495-501(2004).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NPM1.
RX   PubMed=15388344; DOI=10.1016/j.febslet.2004.08.047;
RA   Yao J., Fu C., Ding X., Guo Z., Zenreski A., Chen Y., Ahmed K., Liao J.,
RA   Dou Z., Yao X.;
RT   "Nek2A kinase regulates the localization of numatrin to centrosome in
RT   mitosis.";
RL   FEBS Lett. 575:112-118(2004).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, ACTIVITY REGULATION, INTERACTION WITH
RP   NEK11, AND MUTAGENESIS OF LYS-37.
RX   PubMed=15161910; DOI=10.1074/jbc.m404104200;
RA   Noguchi K., Fukazawa H., Murakami Y., Uehara Y.;
RT   "Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells.";
RL   J. Biol. Chem. 279:32716-32727(2004).
RN   [16]
RP   FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH PPP1CA AND PPP1CC.
RX   PubMed=17283141; DOI=10.1158/0008-5472.can-06-3071;
RA   Mi J., Guo C., Brautigan D.L., Larner J.M.;
RT   "Protein phosphatase-1alpha regulates centrosome splitting through Nek2.";
RL   Cancer Res. 67:1082-1089(2007).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SGO1.
RX   PubMed=17621308; DOI=10.1038/cr.2007.55;
RA   Fu G., Ding X., Yuan K., Aikhionbare F., Yao J., Cai X., Jiang K., Yao X.;
RT   "Phosphorylation of human Sgo1 by NEK2A is essential for chromosome
RT   congression in mitosis.";
RL   Cell Res. 17:608-618(2007).
RN   [18]
RP   ALTERNATIVE SPLICING, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION,
RP   AUTOPHOSPHORYLATION, AND INTERACTION WITH PPP1A.
RX   PubMed=17626005; DOI=10.1074/jbc.m704969200;
RA   Wu W., Baxter J.E., Wattam S.L., Hayward D.G., Fardilha M., Knebel A.,
RA   Ford E.M., da Cruz e Silva E.F., Fry A.M.;
RT   "Alternative splicing controls nuclear translocation of the cell cycle-
RT   regulated Nek2 kinase.";
RL   J. Biol. Chem. 282:26431-26440(2007).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH CTNB1.
RX   PubMed=18086858; DOI=10.1101/gad.1596308;
RA   Bahmanyar S., Kaplan D.D., Deluca J.G., Giddings T.H. Jr., O'Toole E.T.,
RA   Winey M., Salmon E.D., Casey P.J., Nelson W.J., Barth A.I.;
RT   "beta-Catenin is a Nek2 substrate involved in centrosome separation.";
RL   Genes Dev. 22:91-105(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-397, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH NDC80.
RX   PubMed=18297113; DOI=10.1038/onc.2008.34;
RA   Du J., Cai X., Yao J., Ding X., Wu Q., Pei S., Jiang K., Zhang Y., Wang W.,
RA   Shi Y., Lai Y., Shen J., Teng M., Huang H., Fei Q., Reddy E.S., Zhu J.,
RA   Jin C., Yao X.;
RT   "The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule
RT   attachment stability.";
RL   Oncogene 27:4107-4114(2008).
RN   [23]
RP   ACTIVITY REGULATION.
RX   PubMed=19941817; DOI=10.1016/j.molcel.2009.09.038;
RA   Richards M.W., O'Regan L., Mas-Droux C., Blot J.M., Cheung J., Hoelder S.,
RA   Fry A.M., Bayliss R.;
RT   "An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase
RT   is released through binding of Nek9.";
RL   Mol. Cell 36:560-570(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   INTERACTION WITH PCNT.
RX   PubMed=20599736; DOI=10.1016/j.bbrc.2010.06.063;
RA   Matsuo K., Nishimura T., Hayakawa A., Ono Y., Takahashi M.;
RT   "Involvement of a centrosomal protein kendrin in the maintenance of
RT   centrosome cohesion by modulating Nek2A kinase activity.";
RL   Biochem. Biophys. Res. Commun. 398:217-223(2010).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAD2L1 AND CDC20.
RX   PubMed=20034488; DOI=10.1016/j.yexmp.2009.12.004;
RA   Liu Q., Hirohashi Y., Du X., Greene M.I., Wang Q.;
RT   "Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism
RT   for aneuploidy in cancer.";
RL   Exp. Mol. Pathol. 88:225-233(2010).
RN   [27]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STK3/MST2 AND SAV1, AND
RP   PHOSPHORYLATION AT SER-356; SER-365; SER-406 AND SER-438.
RX   PubMed=21076410; DOI=10.1038/ncb2120;
RA   Mardin B.R., Lange C., Baxter J.E., Hardy T., Scholz S.R., Fry A.M.,
RA   Schiebel E.;
RT   "Components of the Hippo pathway cooperate with Nek2 kinase to regulate
RT   centrosome disjunction.";
RL   Nat. Cell Biol. 12:1166-1176(2010).
RN   [28]
RP   DOMAIN LEUCINE-ZIPPER.
RX   PubMed=21669869; DOI=10.1074/jbc.m110.196972;
RA   Croasdale R., Ivins F.J., Muskett F., Daviter T., Scott D.J., Hardy T.,
RA   Smerdon S.J., Fry A.M., Pfuhl M.;
RT   "An undecided coiled-coil: the leucine zipper of NEK2 kinase exhibits
RT   atypical conformational exchange dynamics.";
RL   J. Biol. Chem. 286:27537-27547(2011).
RN   [29]
RP   REVIEW.
RX   PubMed=16280549; DOI=10.1242/jcs.02681;
RA   Quarmby L.M., Mahjoub M.R.;
RT   "Caught Nek-ing: cilia and centrioles.";
RL   J. Cell Sci. 118:5161-5169(2005).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-171; SER-184 AND SER-300, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   INVOLVEMENT IN RP67.
RX   PubMed=24043777; DOI=10.1073/pnas.1308243110;
RA   Nishiguchi K.M., Tearle R.G., Liu Y.P., Oh E.C., Miyake N., Benaglio P.,
RA   Harper S., Koskiniemi-Kuendig H., Venturini G., Sharon D., Koenekoop R.K.,
RA   Nakamura M., Kondo M., Ueno S., Yasuma T.R., Beckmann J.S., Ikegawa S.,
RA   Matsumoto N., Terasaki H., Berson E.L., Katsanis N., Rivolta C.;
RT   "Whole genome sequencing in patients with retinitis pigmentosa reveals
RT   pathogenic DNA structural changes and NEK2 as a new disease gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:16139-16144(2013).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH CNTLN AND CEP68.
RX   PubMed=24554434; DOI=10.1242/jcs.139451;
RA   Fang G., Zhang D., Yin H., Zheng L., Bi X., Yuan L.;
RT   "Centlein mediates an interaction between C-Nap1 and Cep68 to maintain
RT   centrosome cohesion.";
RL   J. Cell Sci. 127:1631-1639(2014).
RN   [33]
RP   FUNCTION.
RX   PubMed=25704143; DOI=10.1016/j.ejcb.2015.01.004;
RA   Man X., Megraw T.L., Lim Y.P.;
RT   "Cep68 can be regulated by Nek2 and SCF complex.";
RL   Eur. J. Cell Biol. 94:162-172(2015).
RN   [34]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CEP85.
RX   PubMed=26220856; DOI=10.1242/jcs.171637;
RA   Chen C., Tian F., Lu L., Wang Y., Xiao Z., Yu C., Yu X.;
RT   "Characterization of Cep85 - a new antagonist of Nek2A that is involved in
RT   the regulation of centrosome disjunction.";
RL   J. Cell Sci. 128:3290-3303(2015).
RN   [35]
RP   ERRATUM OF PUBMED:26220856.
RX   PubMed=26471995; DOI=10.1242/jcs.180463;
RA   Chen C., Tian F., Lu L., Wang Y., Xiao Z., Yu C., Yu X.;
RL   J. Cell Sci. 128:3837-3837(2015).
RN   [36]
RP   FUNCTION, INTERACTION WITH CCDC102B, AND MUTAGENESIS OF LYS-37.
RX   PubMed=30404835; DOI=10.1242/jcs.222901;
RA   Xia Y., Huang N., Chen Z., Li F., Fan G., Ma D., Chen J., Teng J.;
RT   "CCDC102B functions in centrosome linker assembly and centrosome
RT   cohesion.";
RL   J. Cell Sci. 131:0-0(2018).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-271 IN COMPLEX WITH INHIBITOR
RP   SU11652, PHOSPHORYLATION AT THR-170; SER-171; THR-175; THR-179; SER-241;
RP   SER-356; SER-387; SER-390; SER-397; SER-402 AND SER-428, MUTAGENESIS OF
RP   LYS-37; ASP-141; THR-170; SER-171; THR-175; THR-179 AND SER-241, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17197699; DOI=10.1074/jbc.m609721200;
RA   Rellos P., Ivins F.J., Baxter J.E., Pike A., Nott T.J., Parkinson D.M.,
RA   Das S., Howell S., Fedorov O., Shen Q.Y., Fry A.M., Knapp S., Smerdon S.J.;
RT   "Structure and regulation of the human Nek2 centrosomal kinase.";
RL   J. Biol. Chem. 282:6833-6842(2007).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-354 AND TYR-410.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase which is involved in the control of centrosome
CC       separation and bipolar spindle formation in mitotic cells and chromatin
CC       condensation in meiotic cells. Regulates centrosome separation
CC       (essential for the formation of bipolar spindles and high-fidelity
CC       chromosome separation) by phosphorylating centrosomal proteins such as
CC       CROCC, CEP250 and NINL, resulting in their displacement from the
CC       centrosomes. Regulates kinetochore microtubule attachment stability in
CC       mitosis via phosphorylation of NDC80. Involved in regulation of mitotic
CC       checkpoint protein complex via phosphorylation of CDC20 and MAD2L1.
CC       Plays an active role in chromatin condensation during the first meiotic
CC       division through phosphorylation of HMGA2. Phosphorylates: PPP1CC;
CC       SGO1; NECAB3 and NPM1. Essential for localization of MAD2L1 to
CC       kinetochore and MAPK1 and NPM1 to the centrosome. Phosphorylates CEP68
CC       and CNTLN directly or indirectly (PubMed:24554434). NEK2-mediated
CC       phosphorylation of CEP68 promotes CEP68 dissociation from the
CC       centrosome and its degradation at the onset of mitosis
CC       (PubMed:25704143). Involved in the regulation of centrosome disjunction
CC       (PubMed:26220856). Phosphorylates CCDC102B either directly or
CC       indirectly which causes CCDC102B to dissociate from the centrosome and
CC       allows for centrosome separation (PubMed:30404835).
CC       {ECO:0000269|PubMed:11742531, ECO:0000269|PubMed:12857871,
CC       ECO:0000269|PubMed:14978040, ECO:0000269|PubMed:15358203,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:17283141,
CC       ECO:0000269|PubMed:17621308, ECO:0000269|PubMed:17626005,
CC       ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18297113,
CC       ECO:0000269|PubMed:20034488, ECO:0000269|PubMed:21076410,
CC       ECO:0000269|PubMed:24554434, ECO:0000269|PubMed:25704143,
CC       ECO:0000269|PubMed:26220856, ECO:0000269|PubMed:30404835}.
CC   -!- FUNCTION: [Isoform 1]: Phosphorylates and activates NEK11 in G1/S-
CC       arrested cells. {ECO:0000269|PubMed:15161910}.
CC   -!- FUNCTION: [Isoform 2]: Not present in the nucleolus and, in contrast to
CC       isoform 1, does not phosphorylate and activate NEK11 in G1/S-arrested
CC       cells. {ECO:0000269|PubMed:15161910}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Isoform 1 is inhibited by ionizing radiation in
CC       the presence of PPP1CA. Its catalytic activity is inhibited by the
CC       inhibitor CCT241950. In the presence of this inhibitor, displays an
CC       autoinhibited conformation: Tyr-70 side chain points into the active
CC       site, interacts with the activation loop, and blocks the alphaC helix.
CC       {ECO:0000269|PubMed:15161910, ECO:0000269|PubMed:17283141,
CC       ECO:0000269|PubMed:19941817}.
CC   -!- SUBUNIT: Isoform 1, isoform 2 and isoform 4 form homo- and
CC       heterodimers. Interacts with NECAB3 and HMGA2 (By similarity). Isoform
CC       1 interacts with CDC20, CTNB1, MAD1L1, MAPK, NEK11, NPM1, NDC80, PCNT
CC       and SGO1 (PubMed:14978040, PubMed:15358203, PubMed:15388344,
CC       PubMed:15161910, PubMed:17621308, PubMed:18086858, PubMed:18297113,
CC       PubMed:20599736, PubMed:20034488). Isoform 1 interacts with STK3/MST2
CC       (via SARAH domain) and SAV1 (via SARAH domain) (PubMed:21076410).
CC       Isoform 1 and isoform 2 interact with MAD2L1 (PubMed:20034488). Isoform
CC       1 and isoform 4 interact with PPP1CA and PPP1CC (PubMed:15659832,
CC       PubMed:17283141). Interacts with CEP68; the interaction leads to
CC       phosphorylation of CEP68. Interacts with CNTLN; the interaction leads
CC       to phosphorylation of CNTLN (PubMed:24554434). Isoform 1 interacts with
CC       CEP85 (PubMed:26220856). Interacts with CCDC102B; the interaction leads
CC       to phosphorylation of CCDC102B (PubMed:30404835).
CC       {ECO:0000250|UniProtKB:O35942, ECO:0000269|PubMed:14978040,
CC       ECO:0000269|PubMed:15161910, ECO:0000269|PubMed:15358203,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:15659832,
CC       ECO:0000269|PubMed:17197699, ECO:0000269|PubMed:17283141,
CC       ECO:0000269|PubMed:17621308, ECO:0000269|PubMed:17626005,
CC       ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18297113,
CC       ECO:0000269|PubMed:20034488, ECO:0000269|PubMed:20599736,
CC       ECO:0000269|PubMed:21076410, ECO:0000269|PubMed:24554434,
CC       ECO:0000269|PubMed:26220856, ECO:0000269|PubMed:30404835}.
CC   -!- INTERACTION:
CC       P51955; Q9UJX5: ANAPC4; NbExp=6; IntAct=EBI-633182, EBI-2554854;
CC       P51955; P30260: CDC27; NbExp=2; IntAct=EBI-633182, EBI-994813;
CC       P51955; Q5T7B8: KIF24; NbExp=7; IntAct=EBI-633182, EBI-2556811;
CC       P51955; Q8NG66: NEK11; NbExp=5; IntAct=EBI-633182, EBI-633195;
CC       P51955; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-633182, EBI-356289;
CC       P51955; Q6GQ04: cdc27.S; Xeno; NbExp=2; IntAct=EBI-633182, EBI-995003;
CC       P51955-1; Q8NG66: NEK11; NbExp=2; IntAct=EBI-687792, EBI-633195;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:15161910}. Cytoplasm. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome {ECO:0000269|PubMed:14654843,
CC       ECO:0000269|PubMed:26220856}. Cytoplasm, cytoskeleton, spindle pole.
CC       Chromosome, centromere, kinetochore. Chromosome, centromere
CC       {ECO:0000250}. Note=STK3/MST2 and SAV1 are required for its targeting
CC       to the centrosome. Colocalizes with SGO1 and MAD1L1 at the kinetochore.
CC       Not associated with kinetochore in the interphase but becomes
CC       associated with it upon the breakdown of the nuclear envelope. Has a
CC       nucleolar targeting/ retention activity via a coiled-coil domain at the
CC       C-terminal end.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Note=Predominantly
CC       cytoplasmic.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Note=Predominantly nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Nek2A;
CC         IsoId=P51955-1; Sequence=Displayed;
CC       Name=2; Synonyms=Nek2B;
CC         IsoId=P51955-2; Sequence=VSP_015578, VSP_015579;
CC       Name=3;
CC         IsoId=P51955-3; Sequence=VSP_015576, VSP_015577;
CC       Name=4; Synonyms=Nek2C, Nek2A-T;
CC         IsoId=P51955-4; Sequence=VSP_041758;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in peripheral
CC       blood T-cells and a wide variety of transformed cell types. Isoform 1
CC       and isoform 4 are expressed in the testis. Up-regulated in various
CC       cancer cell lines, as well as primary breast tumors.
CC       {ECO:0000269|PubMed:11742531, ECO:0000269|PubMed:15659832}.
CC   -!- INDUCTION: Expression and activity peak in the G2 phase of the mitotic
CC       cycle and decrease once the cells have entered mitosis due to
CC       degradation by the anaphase promoting complex APC/C-CDC20. In G1 phase,
CC       both isoform 1 and isoform 2 are almost undetectable. However, at the
CC       G1/S transition, there is an increase in expression of both isoforms
CC       which then remain at this increased level throughout S and G2. At the
CC       onset of mitosis, isoform 1 undergoes a rapid disappearance whereas
CC       isoform 2 continues to be present at about the same level as in G2.
CC       During the rest of mitosis, isoform 1 remains absent, while isoform 2
CC       only begins to decline upon re-entry into the next G1 phase.
CC       {ECO:0000269|PubMed:11742531, ECO:0000269|PubMed:26220856}.
CC   -!- DOMAIN: The leucine-zipper domain is required for its dimerization and
CC       activation. {ECO:0000269|PubMed:21669869}.
CC   -!- PTM: Activated by autophosphorylation. Protein phosphatase 1 represses
CC       autophosphorylation and activation of isoform 1 by dephosphorylation.
CC       Phosphorylation by STK3/MST2 is necessary for its localization to the
CC       centrosome. {ECO:0000269|PubMed:17197699, ECO:0000269|PubMed:21076410}.
CC   -!- DISEASE: Retinitis pigmentosa 67 (RP67) [MIM:615565]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies. Retinitis
CC       pigmentosa is characterized by retinal pigment deposits visible on
CC       fundus examination and primary loss of rod photoreceptor cells followed
CC       by secondary loss of cone photoreceptors. Patients typically have night
CC       vision blindness and loss of midperipheral visual field. As their
CC       condition progresses, they lose their far peripheral visual field and
CC       eventually central vision as well. {ECO:0000269|PubMed:24043777}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr
CC       protein kinase family. NIMA subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH65932.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z29066; CAA82309.1; -; mRNA.
DR   EMBL; AY045701; AAK92212.1; -; mRNA.
DR   EMBL; U11050; AAA19558.1; -; mRNA.
DR   EMBL; BT019729; AAV38534.1; -; mRNA.
DR   EMBL; AK223353; BAD97073.1; -; mRNA.
DR   EMBL; AC096637; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356310; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC043502; AAH43502.2; -; mRNA.
DR   EMBL; BC052807; AAH52807.1; -; mRNA.
DR   EMBL; BC065932; AAH65932.1; ALT_FRAME; mRNA.
DR   EMBL; Z25425; CAA80912.1; -; mRNA.
DR   EMBL; AY863109; AAW56418.1; -; mRNA.
DR   CCDS; CCDS1500.1; -. [P51955-1]
DR   CCDS; CCDS55682.1; -. [P51955-2]
DR   PIR; G01452; G01452.
DR   PIR; I38215; I38215.
DR   RefSeq; NP_001191111.1; NM_001204182.1.
DR   RefSeq; NP_001191112.1; NM_001204183.1. [P51955-2]
DR   RefSeq; NP_002488.1; NM_002497.3. [P51955-1]
DR   RefSeq; XP_005273204.1; XM_005273147.1. [P51955-4]
DR   PDB; 2JAV; X-ray; 2.20 A; A=1-271.
DR   PDB; 2W5A; X-ray; 1.55 A; A=1-271.
DR   PDB; 2W5B; X-ray; 2.40 A; A=1-271.
DR   PDB; 2W5H; X-ray; 2.33 A; A=1-271.
DR   PDB; 2WQO; X-ray; 2.17 A; A=1-271.
DR   PDB; 2XK3; X-ray; 2.20 A; A=1-271.
DR   PDB; 2XK4; X-ray; 2.10 A; A=1-271.
DR   PDB; 2XK6; X-ray; 2.20 A; A=1-271.
DR   PDB; 2XK7; X-ray; 1.99 A; A=1-271.
DR   PDB; 2XK8; X-ray; 2.00 A; A=1-271.
DR   PDB; 2XKC; X-ray; 2.50 A; A=1-271.
DR   PDB; 2XKD; X-ray; 1.96 A; A=1-271.
DR   PDB; 2XKE; X-ray; 2.20 A; A=1-271.
DR   PDB; 2XKF; X-ray; 2.35 A; A=1-271.
DR   PDB; 2XNM; X-ray; 1.85 A; A=1-271.
DR   PDB; 2XNN; X-ray; 2.50 A; A=1-271.
DR   PDB; 2XNO; X-ray; 1.98 A; A=1-271.
DR   PDB; 2XNP; X-ray; 1.98 A; A=1-271.
DR   PDB; 4A4X; X-ray; 2.40 A; A=1-271.
DR   PDB; 4AFE; X-ray; 2.60 A; A=1-271.
DR   PDB; 5M51; X-ray; 1.90 A; A=1-271.
DR   PDB; 5M53; X-ray; 1.90 A; A=1-271.
DR   PDB; 5M55; X-ray; 2.40 A; A=1-271.
DR   PDB; 5M57; X-ray; 2.30 A; A=1-271.
DR   PDB; 6SGD; X-ray; 2.00 A; A=1-271.
DR   PDB; 6SGH; X-ray; 3.00 A; A=1-271.
DR   PDB; 6SGI; X-ray; 2.30 A; A=1-271.
DR   PDB; 6SGK; X-ray; 2.00 A; A=1-271.
DR   PDB; 6SK9; X-ray; 2.00 A; A=1-271.
DR   PDB; 6TM5; EM; 3.90 A; Q/S=1-445.
DR   PDBsum; 2JAV; -.
DR   PDBsum; 2W5A; -.
DR   PDBsum; 2W5B; -.
DR   PDBsum; 2W5H; -.
DR   PDBsum; 2WQO; -.
DR   PDBsum; 2XK3; -.
DR   PDBsum; 2XK4; -.
DR   PDBsum; 2XK6; -.
DR   PDBsum; 2XK7; -.
DR   PDBsum; 2XK8; -.
DR   PDBsum; 2XKC; -.
DR   PDBsum; 2XKD; -.
DR   PDBsum; 2XKE; -.
DR   PDBsum; 2XKF; -.
DR   PDBsum; 2XNM; -.
DR   PDBsum; 2XNN; -.
DR   PDBsum; 2XNO; -.
DR   PDBsum; 2XNP; -.
DR   PDBsum; 4A4X; -.
DR   PDBsum; 4AFE; -.
DR   PDBsum; 5M51; -.
DR   PDBsum; 5M53; -.
DR   PDBsum; 5M55; -.
DR   PDBsum; 5M57; -.
DR   PDBsum; 6SGD; -.
DR   PDBsum; 6SGH; -.
DR   PDBsum; 6SGI; -.
DR   PDBsum; 6SGK; -.
DR   PDBsum; 6SK9; -.
DR   PDBsum; 6TM5; -.
DR   AlphaFoldDB; P51955; -.
DR   SMR; P51955; -.
DR   BioGRID; 110826; 127.
DR   CORUM; P51955; -.
DR   IntAct; P51955; 47.
DR   MINT; P51955; -.
DR   STRING; 9606.ENSP00000355966; -.
DR   BindingDB; P51955; -.
DR   ChEMBL; CHEMBL3835; -.
DR   DrugBank; DB07180; 5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P51955; -.
DR   GuidetoPHARMACOLOGY; 2117; -.
DR   iPTMnet; P51955; -.
DR   PhosphoSitePlus; P51955; -.
DR   BioMuta; NEK2; -.
DR   DMDM; 1709252; -.
DR   CPTAC; CPTAC-1258; -.
DR   CPTAC; CPTAC-1259; -.
DR   EPD; P51955; -.
DR   jPOST; P51955; -.
DR   MassIVE; P51955; -.
DR   MaxQB; P51955; -.
DR   PaxDb; P51955; -.
DR   PeptideAtlas; P51955; -.
DR   PRIDE; P51955; -.
DR   ProteomicsDB; 56453; -. [P51955-1]
DR   ProteomicsDB; 56454; -. [P51955-2]
DR   ProteomicsDB; 56455; -. [P51955-3]
DR   ProteomicsDB; 56456; -. [P51955-4]
DR   Antibodypedia; 4308; 463 antibodies from 37 providers.
DR   DNASU; 4751; -.
DR   Ensembl; ENST00000366998.4; ENSP00000355965.3; ENSG00000117650.13. [P51955-2]
DR   Ensembl; ENST00000366999.9; ENSP00000355966.4; ENSG00000117650.13. [P51955-1]
DR   GeneID; 4751; -.
DR   KEGG; hsa:4751; -.
DR   MANE-Select; ENST00000366999.9; ENSP00000355966.4; NM_002497.4; NP_002488.1.
DR   UCSC; uc001hir.3; human. [P51955-1]
DR   CTD; 4751; -.
DR   DisGeNET; 4751; -.
DR   GeneCards; NEK2; -.
DR   HGNC; HGNC:7745; NEK2.
DR   HPA; ENSG00000117650; Group enriched (bone marrow, lymphoid tissue, testis).
DR   MalaCards; NEK2; -.
DR   MIM; 604043; gene.
DR   MIM; 615565; phenotype.
DR   neXtProt; NX_P51955; -.
DR   OpenTargets; ENSG00000117650; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA31546; -.
DR   VEuPathDB; HostDB:ENSG00000117650; -.
DR   eggNOG; KOG1826; Eukaryota.
DR   GeneTree; ENSGT00940000156989; -.
DR   HOGENOM; CLU_000288_63_23_1; -.
DR   InParanoid; P51955; -.
DR   OMA; PSRPEDY; -.
DR   OrthoDB; 1290401at2759; -.
DR   PhylomeDB; P51955; -.
DR   TreeFam; TF101184; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P51955; -.
DR   Reactome; R-HSA-179409; APC-Cdc20 mediated degradation of Nek2A.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-380320; Recruitment of NuMA to mitotic centrosomes.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SignaLink; P51955; -.
DR   SIGNOR; P51955; -.
DR   BioGRID-ORCS; 4751; 56 hits in 1103 CRISPR screens.
DR   ChiTaRS; NEK2; human.
DR   EvolutionaryTrace; P51955; -.
DR   GeneWiki; NEK2; -.
DR   GenomeRNAi; 4751; -.
DR   Pharos; P51955; Tchem.
DR   PRO; PR:P51955; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P51955; protein.
DR   Bgee; ENSG00000117650; Expressed in sperm and 144 other tissues.
DR   ExpressionAtlas; P51955; baseline and differential.
DR   Genevisible; P51955; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0030496; C:midbody; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0032991; C:protein-containing complex; IMP:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0001824; P:blastocyst development; IEA:Ensembl.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0051299; P:centrosome separation; IDA:UniProtKB.
DR   GO; GO:0007059; P:chromosome segregation; IDA:UniProtKB.
DR   GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc.
DR   GO; GO:0000070; P:mitotic sister chromatid segregation; IEA:Ensembl.
DR   GO; GO:0090307; P:mitotic spindle assembly; IEA:Ensembl.
DR   GO; GO:1903126; P:negative regulation of centriole-centriole cohesion; IMP:UniProtKB.
DR   GO; GO:0043392; P:negative regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:UniProtKB.
DR   GO; GO:0046602; P:regulation of mitotic centrosome separation; IMP:UniProtKB.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0051225; P:spindle assembly; TAS:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division;
KW   Centromere; Chromosome; Chromosome partition; Coiled coil; Cytoplasm;
KW   Cytoskeleton; Kinase; Kinetochore; Magnesium; Meiosis; Metal-binding;
KW   Microtubule; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Retinitis pigmentosa; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..445
FT                   /note="Serine/threonine-protein kinase Nek2"
FT                   /id="PRO_0000086421"
FT   DOMAIN          8..271
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          264..445
FT                   /note="Interaction with PCNT"
FT                   /evidence="ECO:0000269|PubMed:20599736"
FT   REGION          301..445
FT                   /note="Interaction with CEP85"
FT                   /evidence="ECO:0000269|PubMed:26220856"
FT   REGION          306..334
FT                   /note="Leucine-zipper"
FT   REGION          329..445
FT                   /note="Necessary for interaction with MAD1L1"
FT                   /evidence="ECO:0000269|PubMed:14978040"
FT   REGION          333..370
FT                   /note="Required for microtubule binding and for
FT                   localization to the centrosomes"
FT   REGION          403..439
FT                   /note="Interaction with SAV1 and STK3/MST2"
FT                   /evidence="ECO:0000269|PubMed:21076410"
FT   COILED          303..362
FT                   /evidence="ECO:0000255"
FT   COILED          406..430
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        141
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         14..22
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         37
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         170
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:17197699"
FT   MOD_RES         171
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:17197699,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         175
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MOD_RES         179
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MOD_RES         184
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         241
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MOD_RES         296
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         300
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         356
FT                   /note="Phosphoserine; by STK3/MST2"
FT                   /evidence="ECO:0000269|PubMed:17197699,
FT                   ECO:0000269|PubMed:21076410"
FT   MOD_RES         365
FT                   /note="Phosphoserine; by STK3/MST2"
FT                   /evidence="ECO:0000269|PubMed:21076410"
FT   MOD_RES         387
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MOD_RES         390
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MOD_RES         397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17197699,
FT                   ECO:0007744|PubMed:18088087"
FT   MOD_RES         402
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MOD_RES         406
FT                   /note="Phosphoserine; by STK3/MST2"
FT                   /evidence="ECO:0000269|PubMed:21076410"
FT   MOD_RES         428
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MOD_RES         438
FT                   /note="Phosphoserine; by STK3/MST2"
FT                   /evidence="ECO:0000269|PubMed:21076410"
FT   VAR_SEQ         323..326
FT                   /note="REER -> KKKK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015576"
FT   VAR_SEQ         327..445
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015577"
FT   VAR_SEQ         371..384
FT                   /note="ELLNLPSSVIKKKV -> GMRINLVNRSWCYK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11742531"
FT                   /id="VSP_015578"
FT   VAR_SEQ         371..378
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15659832"
FT                   /id="VSP_041758"
FT   VAR_SEQ         385..445
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11742531"
FT                   /id="VSP_015579"
FT   VARIANT         354
FT                   /note="N -> S (in dbSNP:rs2230489)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.5"
FT                   /id="VAR_019990"
FT   VARIANT         410
FT                   /note="C -> Y (in dbSNP:rs56102977)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040907"
FT   MUTAGEN         37
FT                   /note="K->R: Loss of kinase activity and of ability to
FT                   activate NEK11. Loss of phosphorylation of CCDC102B."
FT                   /evidence="ECO:0000269|PubMed:15161910,
FT                   ECO:0000269|PubMed:17197699, ECO:0000269|PubMed:30404835"
FT   MUTAGEN         141
FT                   /note="D->A: Loss of autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         170
FT                   /note="T->A: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         170
FT                   /note="T->E: Kinase activity increased by two fold."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         171
FT                   /note="S->A: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         171
FT                   /note="S->D: Kinase activity increased by two fold."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         175
FT                   /note="T->A: Kinase activity decreased by two fold."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         175
FT                   /note="T->E: Kinase activity increased by two fold."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         179
FT                   /note="T->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         179
FT                   /note="T->E: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         241
FT                   /note="S->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   MUTAGEN         241
FT                   /note="S->D: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17197699"
FT   CONFLICT        84..85
FT                   /note="IV -> LY (in Ref. 8; CAA80912)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        325
FT                   /note="E -> K (in Ref. 5; BAD97073)"
FT                   /evidence="ECO:0000305"
FT   HELIX           5..7
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          8..16
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          18..27
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   TURN            28..30
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          33..40
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           41..43
FT                   /evidence="ECO:0007829|PDB:6SGK"
FT   HELIX           46..61
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          70..76
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           77..79
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          81..87
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           94..103
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           110..130
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           144..146
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          147..149
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          151..153
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   STRAND          155..157
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           162..165
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           171..177
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           180..182
FT                   /evidence="ECO:0007829|PDB:5M53"
FT   HELIX           185..189
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           195..211
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           221..230
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           242..251
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           256..258
FT                   /evidence="ECO:0007829|PDB:2W5A"
FT   HELIX           262..266
FT                   /evidence="ECO:0007829|PDB:2W5A"
SQ   SEQUENCE   445 AA;  51763 MW;  D33A37778ABB6D9E CRC64;
     MPSRAEDYEV LYTIGTGSYG RCQKIRRKSD GKILVWKELD YGSMTEAEKQ MLVSEVNLLR
     ELKHPNIVRY YDRIIDRTNT TLYIVMEYCE GGDLASVITK GTKERQYLDE EFVLRVMTQL
     TLALKECHRR SDGGHTVLHR DLKPANVFLD GKQNVKLGDF GLARILNHDT SFAKTFVGTP
     YYMSPEQMNR MSYNEKSDIW SLGCLLYELC ALMPPFTAFS QKELAGKIRE GKFRRIPYRY
     SDELNEIITR MLNLKDYHRP SVEEILENPL IADLVADEQR RNLERRGRQL GEPEKSQDSS
     PVLSELKLKE IQLQERERAL KAREERLEQK EQELCVRERL AEDKLARAEN LLKNYSLLKE
     RKFLSLASNP ELLNLPSSVI KKKVHFSGES KENIMRSENS ESQLTSKSKC KDLKKRLHAA
     QLRAQALSDI EKNYQLKSRQ ILGMR
//
